

## 2025 Publication List Abstracts, Posters, Presentations, Articles, & Patents

Ball-Burack M, Menssen A, Eidenschink Brodersen L, et al. A Case of Blinatumomab Efficacy in RAM Immunophenotype/CBFA2T3::GLIS2 Fusion AML. *Pediatr Blood Cancer*. 2025;72(12):e32035. doi:10.1002/pbc.32035

Elgarten C, Alonzo T, Gerbing R, et al. Post-transplant maintenance with sorafenib is safe and effective in pediatric patients with har FLT3/ITD AML: A report from the Children's oncology group protocol AAML1031. *Blood*. 2025;146(Supplement 1):1644-1644. doi:https://doi.org/10.1182/blood-2025-1644

Menssen A, Cook J, Alonzo T, et al. Analysis of 3346 patients from the combined Children's Oncology Group AML studies further characterizes RAM immunophenotype AML and reveals other associated phenotypes and genetic drivers. *Blood*. 2025;146(Supplement 1):337-337. doi:https://doi.org/10.1182/blood-2025-337

Menssen A, Ashango A, Alonzo T, et al. FLT3 (CD135) expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib therapy: A report from the Children's Oncology Group AAML1031 protocol. *Blood*. 2025;146(Supplement 1):5256-5256. doi:https://doi.org/10.1182/blood-2025-5256

Tarlock K, Summers C, Kirkey D, et al. Phase I study of FH FOLR1 CAR T for pediatric patients with FOLR1+/CBFA2T3::GLIS2+ relapsed or refractory Acute Myeloid Leukemia. *Blood*. 2025;146(Supplement 1):4176-4176. doi:https://doi.org/10.1182/blood-2025-4176

Maurer-Granofszky M, Battistutta F, Bouslama B, et al. A novel intercontinental external quality assessment program for flow cytometric measurable residual disease assessment in pediatric AML. *Blood*. 2025;146(Supplement 1):3514-3514. doi:https://doi.org/10.1182/blood-2025-3514

Chen D, Baer M, Niyongere S, et al. Initial results from a phase 2 study of cladribine, cytarabine, and granulocyte-colony stimulating factor with gemtuzumab ozogamicin (CLAG-GO) for the treatment of patients with relapsed/refractory acute myeloid leukemia. *Blood*. 2025;146(Supplement 1):999-999. doi:https://doi.org/10.1182/blood-2025-999

Berman JN, Verma A, Viola SA, et al. Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual Disease. *Blood Advances*. Published online October 22, 2025. doi:https://doi.org/10.1182/bloodadvances.2025017837

# Hematologies, Inc.

Madan A, Anerao A, Mucker D, et al. Emergence and Implications of *DNMT3A* Mutations in Pediatric AML Post-HSCT: A Case Report and Literature Review. *Pediatric Blood & Cancer*. 2025;72(10). doi:<https://doi.org/10.1002/pbc.31905>

Huang BJ, Meyer LK, Alonzo TA, et al. Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*. 2025;43(17):1961-1971. doi:<https://doi.org/10.1200/jco-24-01841>

Huang BJ, Meyer LK, Alonzo TA, et al. Erratum: Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*. 2025;43(24):2757-2757. doi:<https://doi.org/10.1200/jco-25-01516>

Lachowiez CA, Heiblig M, Aspas Requena G, et al. Genetic and Phenotypic correlates of clinical outcomes with Venetoclax in Acute Myeloid Leukemia: The GEN-PHEN-VEN study. *Blood Cancer Discovery*. Published online May 21, 2025. doi:<https://doi.org/10.1158/2643-3230.bcd-24-0256>

Lyvannak S, Sereyleak B, Heng S, et al. Introduction of treatment for children with acute lymphoblastic leukemia in a resource-limited hospital in Cambodia. *Blood Global Hematology*. 2025;1(2):100011. doi:<https://doi.org/10.1016/j.bglo.2025.100011>

Hochberg J, Oesterheld J, Gardenswartz A, et al. Mitoxantrone in combination with clofarabine (MITCL) in children, adolescents and young adults with relapsed/refractory acute leukaemia: final results of a phase I/II trial. *eClinicalMedicine*. 2025;83:103211. doi:<https://doi.org/10.1016/j.eclinm.2025.103211>

DiPersio JF, Koehne G, Shah NN, et al. A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML). *Transplantation and Cellular Therapy*. 2025;31(2):S61-S62. doi:<https://doi.org/10.1016/j.jtct.2025.01.098>

Jacoby MA, Duncavage ED, Khanna A, et al. Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response. *Leukemia*. 2024;39(1):166-177. doi:<https://doi.org/10.1038/s41375-024-02426-0>

System, method, and article for detecting abnormal cells using multi-dimensional analysis; MR Loken, SN Joshi. US Patent App. 18/740,308. 2025

System, method, and article for detecting abnormal cells using multi-dimensional analysis; MR Loken, AP Voigt. US Patent 12,461,105. 2025